Upravlenie lipotoksichnost'yu v debyute sakharnogo diabeta 2 tipa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The rapid expansion of diabetes mellitus and obesity in the world requires urgent measures for the change the lifestyle and intervention of therapy from the early stages of the disease, which allow to avoid the further development of disturbances of carbohydrate and lipid metabolism, as well as their complications. According to recent data, the pathogenetic link for these diseases is represented by lipotoxicity that manifests as a complex of negative effects of fatty acids on the organs and tissues involved in the pathogenesis of diabetes mellitus. This study demonstrates the feasibility of successful management of newly diagnosed type 2 diabetes mellitus by timely and effective influence on body weight under the control of the parameters of glycemic and lipid profiles and markers of lipotoxicity.

Full Text

Restricted Access

References

  1. Diabetes atlas. IDF 2012.
  2. Тутельян В.А. Диетологическая служба Российской Федерации: вопросы стандартизации и персонализации лечебного питания // Практическая диетология 2012. № 4. С. 55-62.
  3. Дедов И.И., Шестакова М.В. Результаты реализации подпрограммы «Сахарный диабет» федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007-2012 годы». М., 2012.
  4. Koro C, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27:17-20.
  5. Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. М., 2013.
  6. Poitout V, Robertson P. Glucolipotoxicity: Fuel Excess and -Cell Dysfunction Endocrine Reviews. 2008;29(3):351-66.
  7. Olofsson C, Collins S, Bengtsson M, et al. Longterm exposure to glucose and lipids inhibits glucose-induced insulin secretion downstream of granule fusion with plasma membrane. Diabetes 2007;56:1888-97.
  8. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci USA 2006; 103:16454-59.
  9. Cnop M, Hannaert J, Hoorens A, Eizirik D, Pipeleers D. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 2001;50:1771-77.
  10. Boden G. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 2002;283:12-9.
  11. Malhi H, Gores GJ. Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2008;28(4):360-69.
  12. Itani S, Ruderman N, Schmieder F, Boden G. Lipid-induced insulinresistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-b. Diabetes 2002;51:2005-11.
  13. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of a Sustained Reduction in Plasma Free Fatty Acid Concentration on Intramuscular Long-Chain Fatty Acyl-CoAs and Insulin Action in Type 2 Diabetic Patients. Diabetes 2005;54(11):3148-53.
  14. Korani M, Firoozrai M, Maleki J, et al. Fatty acid composition of serum lipids in patients with type 2 diabetes. Clin Lab 2012;58( 11-12): 1283-91.
  15. Wang L, Folsom A, Zhi-Jie Zheng, James S, Pankow J, Eckfeldt H for the ARIC Study Investigators. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study1,2,3. Am J Clin Nutr 2003;78(1):91-8.
  16. RosenfalckA, Hendel H, Rasmussen M, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 2002;4(1):19-28.
  17. Hamman RF, Wing RR, Edelstein S, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29:2102-107.
  18. Kelley D, Bray G, Klein S, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: а 1 -year randomized controlled trial. Diabetes Care 2002;25(6): 1033-41.
  19. Аметов А.С. Избранные лекции по эндокринологии. МИА, 2012.
  20. Viollet B, Guigas B, Garcia NS, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122(6):253-70.
  21. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-69.
  22. Argaud D, Roth H, Wiernsperger N, Leverve XM. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 1993; 213:1341-48.
  23. Radziuk J, Zhang Z, Wiernsperger N, Pye S. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 1997;46:1406-13.
  24. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33.
  25. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin Diabetes 2002;51:134-37.
  26. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004;279: 47898-905.
  27. Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009; 196:81 -98.
  28. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K. Mechanism for fatty acid «sparing» effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2002;277:3829-35.
  29. Kim E, Liu NC, Yu IC, et al. Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes 2011;60:1493-503.
  30. Abbasi F. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Diabetes Care 1997;20(12):1863-69.
  31. Cabezas M, van Wijk J, Elte JW, Klop B. Effects of metformin on the regulation of free fatty acids in insulin resistance: a double-blind, placebo-controlled study. J Nutr Metab 2012;2012:394623.
  32. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 2012;35:4731-37.
  33. Gokcel A, Karakose H., Ertorer E., et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001;24:1957-60.
  34. Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obes Relat Metab Disord 1998; 22:38-40.
  35. Gao X, Sun X, Zhao N, et al. Level of free fat acid could be decreased in obese subjects after 6 months treatment with sibutramine. J Shang Med 2002;04:35-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies